pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Kerendia
drug · small molecule
save

finerenone

Marketedupdated 6mo ago
by Bayer AG🔗 ChEMBL
Approved
community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 6 investigational indications.

targets

Mineralocorticoid receptor

all catalysts(0)

nothing on the calendar yet

Trials studying finerenone

  • —An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Practiceactive not recruitingn=1,200
  • phase3A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetescompletedn=242
  • phase3A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunctionrecruitingn=117
  • —An Observational Study, Called FINEXPLORER, to Learn More About How Well Finerenone Works in Adults in Spain With Chronic Kidney Disease (CKD) Linked to Type 2 Diabetes, by Looking at Changes in a CKD Risk Scorerecruitingn=500
  • —An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Koreaactive not recruitingn=529
  • —An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United Statescompletedn=238,038
  • phase3A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)recruitingn=1,500
  • phase3A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuriaactive not recruitingn=219

Patent cliff

source: FDA Orange Book
first barrier falls
Jul 11, 2028
~1.6 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (6)

  • Jul 29, 2035compositionUS RE49826
  • Jul 29, 2035compositionUS RE49826
  • Jul 29, 2035compositionUS RE49826
  • Aug 26, 2033compositionUS 8436180
  • Aug 26, 2033compositionUS 8436180
  • Aug 26, 2033compositionUS 8436180

FDA exclusivities (6)

  • Jul 11, 2028I-970Indication (3y)1.6y
  • Jul 11, 2028I-970Indication (3y)1.6y
  • Jul 11, 2028NSNS1.6y
  • Jul 9, 2026NCENew Chemical Entity (5y)
  • Jul 9, 2026NCENew Chemical Entity (5y)
  • Jul 9, 2026NCENew Chemical Entity (5y)

News(0)

no news has mentioned this drug yet

brand
Kerendia
trade names
Kerendia
generic
finerenone
MOA
Mineralocorticoid receptor antagonist
indication
Chronic Kidney Disease (Chronic Renal Failure)
phase
marketed
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 19m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?